Buccolam® is a leading treatment for prolonged, acute, convulsive seizures (PACS) in infants, children and adolescents, with an extensive customer base across 18 countries in Europe and Israel.
Paul Burns, a partner in Allen & Overy’s Corporate and M&A practice, said: “This is an exciting acquisition for Neuraxpharm to expedite and expand access to this emergency treatment for epileptic children across regions. We’re proud of our work with our international teams, leveraging our global colleagues to benefit our clients.”
Allen & Overy’s cross border experience within the healthcare and pharmaceuticals space played an important role in this transaction, which will bring a critical and highly effective treatment to new markets. The U.S. Corporate and M&A practices worked alongside colleagues in the UK, Spain and Germany to address the cross-border complexities of this transaction. The Allen & Overy team has advised on multiple cross-border deals within the global healthcare and pharmaceuticals space in sub-sectors ranging from medicines and food supplements to cosmetics and medical devices, among others.
Dominik Stühler, a partner in Allen & Overy’s Private Equity practice in Munich, said: “This transaction required detailed understanding of regional healthcare regulations and cross-border M&A considerations, and I’m proud to work on a team that can deliver on all fronts.”
The Allen & Overy team advising Neuraxpharm Group was led by M&A partner Paul Burns, associates Caitlin Hanley and Lucy Cai in New York, supported by London-based Corporate partners Matthew Appleton and Jim Ford, counsel Gareth Irving, associates Megan McMellon, Ben Brooks, Magnus Yadi, associate Marta Guardiola in Madrid, and Private Equity partner Dominik Stühler and counsel Kai Terstiege in Munich. New York-based Senior Associate Keren Livneh advised on the IP aspects of the transaction, with Frankfurt-based partner Heike Weber and associate John Hibbard in New York counseling on Tax elements of the transaction. Hamburg-based counsel Rene Galle and associate Philipp Steinhaeuser delivered specialist Antitrust advice.
